Research programme: antibody therapeutics - Albatroz Therapeutics
Latest Information Update: 03 May 2023
At a glance
- Originator Albatroz Therapeutics
- Developer A STAR; Albatroz Therapeutics
- Class Anti-inflammatories; Antibodies; Antineoplastics; Antirheumatics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Arthritis; Solid tumours